Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
SHENK v. MALLINCKRODT PLC et al
Case Number:
1:17-cv-00145
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
- Barrack Rodos
- Bleichmar Fonti
- Cohen Milstein
- Kessler Topaz
- Levi & Korsinsky
- Murray Murphy
- Paul Hastings
- Paul Weiss
- Stull Stull
- Troutman Pepper
- Tydings & Rosenberg
- Venable LLP
- Wachtell Lipton
Companies
Sectors & Industries:
-
August 02, 2022
Attorneys Get $13M In Fees For Mallinckrodt Securities Deal
A District of Columbia federal judge on Tuesday awarded over $13 million in fees to Barrack Rodos & Bacine, Lowenstein Sandler LLP, and Murray Murphy Moul & Basil LLP for representing the investor class in a $65.75 million settlement of securities claims against drugmaker Mallinckrodt.
-
February 22, 2022
Mallinckrodt Wins Approval Of $66M Securities Deal
A Delaware bankruptcy judge on Tuesday approved a $65.75 million settlement resolving class claims that Mallinckrodt PLC concealed from investors its reliance on federal reimbursements for Acthar gel products.
-
November 19, 2018
Mallinckrodt Urges Court To Toss Investor Suit Over Acthar
Mallinckrodt PLC asked a D.C. federal judge to throw out a stockholder suit Monday, saying the investors can't meet a crucial legal test to show the firm deliberately misled them about reimbursement risks for the drug Acthar.
-
August 31, 2018
Mallinckrodt Investors Defend False Statements Suit
A group of Mallinckrodt PLC investors urged a D.C. federal judge Thursday to keep their consolidated complaint alive, arguing that the company knowingly issued false and misleading statements about one of its key drugs.
-
July 18, 2018
Mallinckrodt Looks To Exit Investor Suit Over Antitrust Deal
Mallinckrodt PLC and its top executives said Tuesday that investors knew of the antitrust risk linked to its infant seizure drug Acthar and have relied on "bad math" in accusing it of lying about the drug's dependence on federal revenue, urging a D.C. federal judge to put an end to the investors' suit.
-
March 12, 2018
Ohio Pension OK'd To Lead Investors Against Mallinckrodt
A D.C. federal judge approved the State Teachers Retirement System of Ohio as lead plaintiff in a class action alleging Mallinckrodt PLC executives lied to shareholders about anti-competitive efforts, rejecting another plaintiff's "speculative" allegation that contributions to Ohio's attorney general leaves the pension's legal team vulnerable.
-
January 23, 2017
Mallinckrodt Hit With Securities Suit After $100M FTC Deal
Just days after it reached a $100 million deal with the Federal Trade Commission and several states to end allegations it had snapped up a monopoly on infant seizure drug Acthar, Mallinckrodt PLC was hit with a proposed shareholder class action alleging executives had long concealed upcoming trouble.